Trial reportAmerican journal of respiratory and critical care medicine2025
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A
Abstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Effectiveness and Safety of Glycopyrronium-Formoterol-Budesonide Triple Therapy in Chronic Obstructive Pulmonary Disease (AIR-FORCE): An Open-Label Multi-Centric Phase 4 Study.Advances in respiratory medicine · 2025Trial
- From airways to arteries: cardiovascular and kidney risk in chronic obstructive pulmonary disease.EClinicalMedicine · 2026Article
- Strategies for therapeutic optimization and proactive care in chronic obstructive pulmonary disease (COPD): an Italian expert opinion.Internal and emergency medicine · 2026Review
- Acute exacerbation of chronic obstructive pulmonary disease as a short-term cardiopulmonary risk window: a time-stratified systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- The systemic impact of acute exacerbations of COPD requiring hospitalisation: a narrative review.ERJ open research · 2026Review
- Association Between Sleep Disorders and Adverse Cardiovascular Outcomes in Patients with Chronic Obstructive Pulmonary Disease: Insights from the UK Biobank.International journal of chronic obstructive pulmonary disease · 2026Article
- Effect of ICS/LAMA/LABA versus LAMA/LABA Therapy on Cardiovascular Benefits in Patients with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Beyond the Lungs: A Narrative Review of Cardiopulmonary Risk Reduction and Management Perspectives in Thai COPD Patients.International journal of chronic obstructive pulmonary disease · 2026Review
- Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database.Frontiers in cardiovascular medicine · 2026Article
- Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial.ERJ open research · 2025Article
- Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study.Advances in therapy · 2025Observational
- Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments.Drugs · 2025Review
- Association of echocardiographic pulmonary hypertension with all-cause mortality in hospitalized AECOPD patients.International journal of cardiology. Heart & vasculature · 2025Article
- What's new in the 2025 GOLD report.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
- Reply to Ariel and Suissa and to Calzetta and Rogliani.American journal of respiratory and critical care medicine · 2025Article
- Reanalyses of ETHOS Triple Therapy Trial Must Consider Forced Discontinuation of Prior Treatment at Randomization.American journal of respiratory and critical care medicine · 2025Article
- Cardiovascular Events in Chronic Obstructive Pulmonary Disease: Squeezing ETHOS Dry for Clinical Evidence at Risk of Type I Error.American journal of respiratory and critical care medicine · 2025Article
- The Role of Inhaled Corticosteroids in Reducing Cardiovascular Risk: Seeing Is Not Always Believing.American journal of respiratory and critical care medicine · 2025Article
- COPD and CVD: the dangerous duo reshaping cardiopulmonary care.The British journal of cardiology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Dave SinghMedicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, United Kingdom.ORCID 0000-0001-8918-7075
Fernando J MartinezDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Massachusetts Chan, Worcester, Massachusetts.ORCID 0000-0002-2412-3182
John R HurstUCL Respiratory, University College London, London, United Kingdom.ORCID 0000-0002-7246-6040
MeiLan K HanDivision of Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-9095-4419
Chris P GaleLeeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom.ORCID 0000-0003-4732-382X
Martin FredrikssonAstraZeneca, Gothenburg, Sweden.
Dobrawa KisielewiczAstraZeneca, Barcelona, Spain.
Alec MushunjeAstraZeneca, Cambridge, United Kingdom.
Charlotta MovitzAstraZeneca, Gothenburg, Sweden.
Nikki OjiliAstraZeneca, Gaithersburg, Maryland; and.
Himanshu ParikhAstraZeneca, Gaithersburg, Maryland; and.
Niki AryaAstraZeneca, Durham, North Carolina.
Karin BowenAstraZeneca, Gaithersburg, Maryland; and.
Mehul PatelAstraZeneca, Cambridge, United Kingdom.ORCID 0000-0003-0435-858X
Funding
AstraZeneca
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bronchodilator AgentsBudesonideCardiovascular DiseasesFormoterol FumarateGlycopyrrolatePulmonary Disease, Chronic ObstructiveAdministration, InhalationAgedDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleMiddle AgedSeverity of Illness IndexTreatment OutcomeBronchodilator AgentsBudesonideFormoterol FumarateGlycopyrrolatebudesonide/glycopyrrolate/formoterol fumaratecardiovascularhospitalizationmortality
Identifiers
PMID
39213002What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.